Shanghai Ark Biopharmaceuticals (ArkBio) has recently released the Phase III clinical trial results for ziresovir, an oral antiviral drug targeting respiratory syncytial virus (RSV) infection in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback